{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:37:42Z","timestamp":1777934262828,"version":"3.51.4"},"reference-count":32,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2016,5,20]],"date-time":"2016-05-20T00:00:00Z","timestamp":1463702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study was to compare clinical outcomes in children undergoing hematopoietic cell transplantation who received levetiracetam versus those who received phenytoin for the prevention of busulfan-induced seizures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was an IRB-approved, single-center, retrospective analysis of pediatric patients receiving intravenous busulfan for hematopoietic cell transplantation conditioning from January 2009 to July 2014. The primary study endpoint was the incidence of seizure during busulfan administration (day \u22128 to 0). Key transplant related-outcomes were also collected, including the incidence of graft rejection, sinusoidal obstruction syndrome, relapse, and death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 20 patients met criteria for inclusion in the study. The population was heterogeneous with regard to the indication for hematopoietic cell transplantation, donor type, stem cell source, and conditioning regimen. Nine patients (45%) received levetiracetam and 11 (55%) received phenytoin for seizure prophylaxis. No seizures or graft rejections were observed in the study population. One relapse, one case of sinusoidal obstruction syndrome, and two deaths occurred in the levetiracetam group, while no relapses, two cases of sinusoidal obstruction syndrome, and one death occurred in the phenytoin group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These data suggest similar safety and effectiveness between levetiracetam and phenytoin for the prevention of busulfan-induced seizures in a small, heterogeneous pediatric hematopoietic cell transplantation population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155216651128","type":"journal-article","created":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T00:46:54Z","timestamp":1463964414000},"page":"344-349","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients"],"prefix":"10.1177","volume":"23","author":[{"given":"Abby E","family":"Floeter","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services, Oregon Health & Science University, Portland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannine S","family":"McCune","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Department of Pharmaceutics, University of Washington, Seattle, USA"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,5,20]]},"reference":[{"key":"bibr1-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404327"},{"key":"bibr2-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1177\/106002809202600107"},{"key":"bibr3-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.12.1502"},{"key":"bibr4-1078155216651128","unstructured":"The Epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care: pharmacological update of clinical guideline 20: The National Institute for Health and Care Excellence\n                      . CG137: London, 2012."},{"key":"bibr5-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2005.06.001"},{"key":"bibr6-1078155216651128","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp120203"},{"key":"bibr7-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-308584"},{"key":"bibr8-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1374"},{"key":"bibr9-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000261917.83337.db"},{"key":"bibr10-1078155216651128","doi-asserted-by":"crossref","unstructured":"Bubalo J, Kovascovics T, Meyers G, et\u00a0al. Clonazepam and levetiracetam for prevention of busulfan-induced seizures: a single-center experience [abstract].\n                      Biol Blood Marrow Transpl\n                      2008;14(2 suppl 2): 165.","DOI":"10.1016\/j.bbmt.2007.12.477"},{"key":"bibr11-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24126"},{"key":"bibr12-1078155216651128","unstructured":"Phenytoin sodium (Dilantin)) package insert, 2012."},{"key":"bibr13-1078155216651128","unstructured":"Keppra (levetiracetam) package insert, 2009."},{"key":"bibr14-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1358\/mf.2004.26.7.863736"},{"key":"bibr15-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.159"},{"key":"bibr16-1078155216651128","unstructured":"Copyright University of Washington 1999\u20132016. UW metabolism and transport drug interaction database. Available at: https:\/\/www.druginteractioninfo.org (accessed 22 January 2016)."},{"key":"bibr17-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.03.012"},{"key":"bibr18-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(88)70096-1"},{"key":"bibr19-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.4.346.30942"},{"key":"bibr20-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1998.tb03148.x"},{"key":"bibr21-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.04.005"},{"key":"bibr22-1078155216651128","unstructured":"Common Terminology Criteria for Adverse Events v4.0. NCI, NIH, DHHS, http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (2009, accessed 28 March 2015)."},{"key":"bibr23-1078155216651128","unstructured":"IV Busulfex Product Information, http:\/\/otsuka-us.com\/products\/Documents\/IVBusulfex.PI.pdf (2015, accessed 10 February 2016)."},{"key":"bibr24-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.07.015"},{"key":"bibr25-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2571-0"},{"key":"bibr26-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31824c2f60"},{"key":"bibr27-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.08.037"},{"key":"bibr28-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702377"},{"key":"bibr29-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.5.1484"},{"key":"bibr30-1078155216651128","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0922-y"},{"key":"bibr31-1078155216651128","doi-asserted-by":"crossref","unstructured":"Mielcarek M, Furlong T, O'Donnell PV, et\u00a0al. Post-transplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.\n                      Blood\n                      2016; 127: 1502\u20131508.","DOI":"10.1182\/blood-2015-10-672071"},{"key":"bibr32-1078155216651128","unstructured":"Fludarabine phosphate (Fludara) package insert, 2003."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155216651128","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155216651128","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155216651128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:16:48Z","timestamp":1777688208000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155216651128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,20]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1177\/1078155216651128"],"URL":"https:\/\/doi.org\/10.1177\/1078155216651128","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,20]]}}}